Skip to main content
SpringerLink
Log in

Topographic mapping of long latency “cognitive” event-related potentials (P 300): a double-blind, placebo-controlled study with amantadine in mild dementia

  • Full Papers
  • Published:
Journal of Neural Transmission - Parkinson's Disease and Dementia Section

Summary

Amantadine is generally used in the prophylaxis of infection with influenza A, in the treatment of Parkinson's disease and in the treatment of neuroleptic side effects. In this study acute effects of amantadine infusions on event-related potentials (ERP) were studied in 20 mildly demented patients diagnosed according to DSM-III-R criteria. Each patient was treated, in randomized order, with 0.2 g amantadinesulfate in 500 ml NaCl and 500 ml NaCl placebo, i.v. over one hour with an interval of two weeks inbetween. ERPs were investigated in an auditory odd-ball paradigm before as well as 5 hours after the infusion. In addition to 17 EEG records, vertical and horizontal EOGs were recorded. After EOG-minimization and visual artifact rejection the peak latencies of the spatial average were determined by an automatic procedure. There was no effect of amantadine on ERP latencies. N 1 of the non-target showed a trend towards amplitude augmentation, P2 amplitude was reduced. As compared to placebo, P300 amplitude of targets was significantly augmented by 3.1 μV (30% of pre-treatment value), confirming the hypothesis that amantadine may influence the P300 amplitude in the sense of an improved availability of cognitive processing resources.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Abt K (1989) Descriptive data analysis (DDA) in quantitative EEG studies. In: Samson-Dollfus D, Guieu JD, Gotman J, Etevenon P (eds) Statistics and topography in quantitative EEG. Elsevier, Amsterdam, pp 150–160

    Google Scholar 

  • Agren H, Osterberg B, Niklasson F, Franzen O (1983) Depression and somatosensory evoked potentials. I. Correlations between SEP and monoamine and purine metabolites in CSF. Biol Psychiatry 18: 635–649

    Google Scholar 

  • Amabile G, Fattapposta F, Pierelli F (1990) Evoked potentials in Parkinson's disease: sensory and cognitive aspects. A review. J Psychophysiol 4: 115–122

    Google Scholar 

  • American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders, 3rd ed-revised (DSM-III-R). American Psychiatric Association, Washington DC

    Google Scholar 

  • Anderer P, Saletu B, Kinsperger K, Semlitsch HV (1987) Topographic brain mapping of EEG in neuropsychopharmacology. Part I. Methodological aspects. Methods Find Exp Clin Pharmacol 9: 371–384

    Google Scholar 

  • Anderer P, Semlitsch HV, Saletu B, Binder GA, Decker KA (1991) A demonstration of the effect of reference on P300-topograpy. J Psychophysiol 5: 97–98 (Abstract)

    Google Scholar 

  • Blackman JD, Towle VL, Lewis GF, Spire J, Polonsky KS (1990) Hypoglycemic thresholds for cognitive dysfunction in humans. Diabetes 39: 828–835

    Google Scholar 

  • Blackwood DHR, Christie JE (1986) The effects of physostigmine on memory and auditory P300 in Alzheimer-type dementia. Biol Psychiatry 21: 557–560

    Google Scholar 

  • Dierks T, Maurer K, Ihl R (1991) Influence of tenilsetam on AEP-P300 in Alzheimer's disease. J Neural Transm (P-D Sect) 1: 49–49

    Google Scholar 

  • Erkulwater S, Pillai R (1989) Amantadine and the end-stage dementia of Alzheimer's type. South Med J 82: 550–554

    Google Scholar 

  • Estrin WJ, Bowler RM, Lash A, Becker CE (1990) Neurotoxicological evaluation of hospital sterilizer workers exposed to ethylene oxide. J Toxicol Clin Toxicol 28: 1–20

    Google Scholar 

  • Fink M (1990) How does convulsive therapy work. Neuropsychopharmacology 3: 73–82

    Google Scholar 

  • Goodin DS (1990) Clinical utility of long latency “cognitive” event-related potentials (P3): the pros. Electroencephalogr Clin Neurophysiol 76: 2–5 (discuss)

    Google Scholar 

  • Goodin DS, Aminoff MJ, Chernoff DN, Hollander H (1990) Long latency event-related potentials in patients infected with human immunodeficiency virus. Ann Neurol 27: 414–419

    Google Scholar 

  • Goodin DS, Squires KC, Henderson BH, Starr A (1978a) Age-related variations in evoked potentials to auditory stimuli in normal human subjects. Electroencephalogr Clin Neurophysiol 45: 447–458

    Google Scholar 

  • Goodin DS, Squires KC, Starr A (1978b) Long-latency event-related components of the auditory evoked potential in dementia. Brain 101: 635–648

    Google Scholar 

  • Gordon E, Kraiuhin C, Harris A, et al (1986a) The differential diagnosis of dementia using P300 latency. Biol Psychiatry 21: 1123–1132

    Google Scholar 

  • Gordon E, Kraiuhin C, Stanfield P, Meares R, Howson A (1986b) The prediction of normal P3 latency and the diagnosis of dementia. Neuropsychologia 24: 823–830

    Google Scholar 

  • Gualtieri B (1988) Pharmacotherapy and the neurobehavioural sequelae of traumatic brain injury. Brain Inj 2: 101–129

    Google Scholar 

  • Gualtieri T, Chandler M, Coons TB, Brown LT (1989) Amantadine: a new clinical profile for traumatic brain injury. Clin Neuropharmacol 12: 258–270

    Google Scholar 

  • Hader W, Duquette P, Auty A, Hashimoto S, Noseworthy J, Sawa G, Brunet D, Nelson R, Gray T, Klein G, Francis G, Lapierre Y, Weinshenker B, Barkas W, Philips S, Girard M, Murray TJ (1987) A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Can J Neurol Sci 14: 273–278

    Google Scholar 

  • Herrmann WM, Abt K, Coppola R, Etevenon ET, Gerber G, Fink M, Gevins AS, Hinrichs H, Itil TM, John ER, Kubicki S, Künkel H, Kugler J, Lehmann D, Petsche H, Rappelsberger P, Röhmel J, Saito M, Saletu B, Scheuler W (1989) International Pharmaco-EEG Group (IPEG). Recommendations for EEG and Evoked Potential Mapping. Neuropsychology 22: 170–176

    Google Scholar 

  • Itil TM (1974) Quantitative pharmaco-electroencephalography. Use of computerized cerebral biopotentials in psychotropic drug research. In: Itil TM (ed) Psychotropic drugs and the human EEG: modern problems of pharmacopsychiatry. Karger, Basel, pp 43–75

    Google Scholar 

  • Itil TM, Saletu B, Coffin C, Klingenberg H (1972) Quantitative EEG changes during thiothixene treatment of chronic schizophrenics. Clin EEG 3: 109–117

    Google Scholar 

  • Ito J, Yamao S, Fukuda H, Mimori Y, Nakamura S (1990) The P300 event-related potentials in dementia of the Alzheimer type. Correlations between P300 and monoamine metabolites. Electroencephalogr Clin Neurophysiol 77: 174–178

    Google Scholar 

  • Janke W, Debus G (1978) Die Eigenschaftswörterliste EWL. Hogrefe, Göttingen Toronto Zürich

    Google Scholar 

  • Jellinger K, Flament H, Reiderer P (1989) Levodopa in the treatment of (pre) senile dementia. Mech Ageing Dev 14: 253–264

    Google Scholar 

  • Johnson R Jr (1986) A triachic model of P300 amplitude. Psychophysiology 23: 367–384

    Google Scholar 

  • Kraiuhin C, Gordon E, Stanfield P, et al (1987) P300 and the effects of aging: relevance to the diagnosis of dementia. Exp Aging Res 12: 187–192

    Google Scholar 

  • Kugler J (1975) Die Beeinflußung von Vigilanz und Bewußtsein durch Amantadinsulfat. Akt Neurol: 43–51

  • Kuskowski MA, Morley G, Malone SM, Dysken MW, Okaya A (1990) Hydergine treatment and psychophysiological measures in primary degenerative dementia. J Geriatr Psychiatry Neurol 3: 41–47

    Google Scholar 

  • Magliero A, Bashore TR, Coles MGH, Donchin E (1984) On the dependence of P300 latency on stimulus evaluation processes. Psychophysiology 21: 171–186

    Google Scholar 

  • Maurer K, Ihl R, Dierks T (1988) Topographie der P300 in der Psychiatrie. II. Kognitive P300-Felder bei Demenz (Topography of P300 in psychiatry. II. Cognitive P300 fields in dementia). EEG EMG 19: 26–29

    Google Scholar 

  • Murray TJ (1985) Amantadine therapy for fatigue in multiple sclerosis. Can J Neurol Sci 12: 251–254

    Google Scholar 

  • Münte TF, Heinze HJ, Scholz M, Künkel H (1988) Effects of a cholinergic nootropic (WEB 1881 FU) on event-related potentials recorded in incidental and intentional memory tasks. Neuropsychobiology 19: 158–168

    Google Scholar 

  • Münte TF, Heinze H, Scholz MB, Bartusch SM, Dietrich DE (1989) Event-related potentials and visual spatial attention: influence of a cholinergic drug. Neuropsychobiology 21: 94–99

    Google Scholar 

  • Neshige R, Barrett G, Shibasaki H (1988) Auditory long latency event-related potentials in Alzheimer's disease and multi-infarct dementia. J Neurol Neurosurg Psychiatry 51: 1120–1125

    Google Scholar 

  • Newton MR, Barrett G, Callanan MM, Towell AD (1989) Cognitive event-related potentials in multiple sclerosis. Brain 112: 1637–1660

    Google Scholar 

  • Nicholson CD (1990) Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. Psychopharmacology 101: 147–159

    Google Scholar 

  • Nobilio D, Faricelli A, Colangelo U, Delre ML, Bazzano S, Onofri M, Gambi D (1990) The effect of levo-acetyl-carnitine on P300 potential. Curr Ther Res Clin Exp 47: 267–277

    Google Scholar 

  • Onofrj M, Ghilardi MF, Faricelli A, Bodis-Wollner I, Calvani M (1987) Effect of levoacetylcarnitine on P300-like potentials of the normal monkey. Drugs Exp Clin Res 13: 407–415

    Google Scholar 

  • Pepeu G, Spignoli G (1990) Neurochemical actions of “nootropic drugs”. Adv Neurol 51: 247–252

    Google Scholar 

  • Peterson PL, Saad J, Nigro MA (1988) The treatment of Friedreich's taxia with amantadine hydrochloride. Neurology 38: 1478–1480

    Google Scholar 

  • Pfefferbaum A, Ford JM, Wenegrat BG, Roth WT, Kopell BS (1984) Clinical application of the P3 component of event-related potentials. I. Normal aging. Electroencephalogr Clin Neurophysiol 59: 85–103

    Google Scholar 

  • Pfefferbaum A, Ford JM, Kraemer HC (1990) Clinical utility of long latency “cognitive” event-related potentials (P3): the cons. Electroencephalogr Clin Neurophysiol 76: 6–12; discus

    Google Scholar 

  • Pierrot-Deseilligny C, Turell E, Penet C, Lebrigand D, Pillon B, Chain F, Agid Y (1989) Increased wave P300 latency in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 52: 656–658

    Google Scholar 

  • Pineda JA, Foote SL, Neville HJ (1989) Effects of locus coeruleus lesions on auditory, long-latency, event-related potentials in monkey. J Neurosci 9: 81–93

    Google Scholar 

  • Pritchard WS, Raz N, August GJ (1987) No effect of chronic fenfluramine on the P300 component of the event-related potential. Int J Neurosci 35: 105–110

    Google Scholar 

  • Puce A, Kalnins RM, Berkovic SF, Donnan GA, Bladin PF (1989) Limbic P3 potentials, seizure localization, and surgical pathology in temporal lobe epilepsy. Ann Neurol 26: 377–385

    Google Scholar 

  • Reisberg B, Ferris SH, de Lean MJ, Crook T (1982) Global deterioration scale (GDS) for age-association cognitive and Alzheimer's disease. In: Reisberg B (ed) Alzheimer's disease. The free press, New York, pp 1136–1139

    Google Scholar 

  • Rockstroh B, Elbert T, Canavan A, Lutzenberger W, Birbaumer N (1989) Slow cortical potentials and behaviour. Urban & Schwarzenberg, Baltimore Munich Vienna

    Google Scholar 

  • Rosenberg GA, Appenzeller O (1988) Amantadine, fatigue, and multiple sclerosis. Arch Neurol 45: 1104–1106

    Google Scholar 

  • Roth WT, Duncan CC, Pfefferbaum A, Timsit-Berthier M (1986) Application of cognitive ERPs in psychiatric patients. In: McCallum WC, Zappoli R, Denoth F (eds) Cerebral psychophysiology: studies in event related-potentials. Elsevier, Amsterdam New York Oxford, pp 419–438

    Google Scholar 

  • Rösler F, Manzey D, Sojka B, Stieglitz RD (1985) Delineation of pharmacopsychological effects by means of endogenous event-related brain potentials: an exemplification with Flupentixol. Neuropsychobiology 13: 81–92

    Google Scholar 

  • Rösler F, Sutton S, Johnson R, Mulder JG, Fabiani M, Plooij-Van Gorsel E, Roth WT (1986) Endogenous ERP components and cognitive constructs. A review. In: McCallum WC, Zappoli R, Denoth F (eds) Cerebral psychophysiology: studies in event-related potentials. Elsevier, Amsterdam New York Oxford, pp 51–92

    Google Scholar 

  • Saletu B (1976) Psychopharmaka, Gehirntätigkeit und Schlaf. Karger, Basel

    Google Scholar 

  • Saletu B (1987) The use of pharmaco-EEG in drug profiling. In: Hindmarch I, Stonier PD (eds) Human psychompharmacology, measures and methods, vol 1. Wiley, Chichester New York Brisbane Toronto Singapore, pp 173–200

    Google Scholar 

  • Saletu B, Anderer P, Kinsperger K, Grünberger J (1987) Topographic brain mapping of EEG in neuropsychopharmacology. Part II. Clinical applications (pharmaco EEG imaging). Methods Find Exp Clin Pharmacol 9: 385–408

    Google Scholar 

  • Saletu B, Semlitsch HV, Anderer P, Resch F, Presslich O, Schuster P (1989) Psychophysiological research in psychiatry and neuropsychopharmacology. II. The investigation of antihypoxidotic/nootropic drugs (tenilsetam and co-dergocrine-mesylate) in elderlies with the Viennese Psychophysiological Test-System (VPTS). Methods Find Exp Clin Pharmacol 11: 43–55

    Google Scholar 

  • Saletu B, Anderer P, Semlitsch HV, Linzmayer L, Grünberger J (1992) Amantadine infusion in mild dementia: acute double-blind placebo-cotrolled EEG mapping and psychometric studies. Arch Gerontol Geriatr (in press)

  • Semlitsch HV, Anderer P, Schuster P, Presslich O (1986) A solution for reliable and valid reduction of ocular artifacts, applied to the P300 ERP. Psychophysiology 23: 695–703

    Google Scholar 

  • Semlitsch HV, Anderer P, Saletu B, Resch F, Presslich O, Schuster P (1989) Psychophysiological research in psychiatry an neuropsychopharmacology. Part I. Methodological aspects of the Viennese Psychophysiological Test-System (VPTS). Methods Find Exp Clin Pharmacol 11: 25–41

    Google Scholar 

  • Semlitsch HV, Anderer P, Saletu B, Hochmayer I (1991) Topographic mapping of Cognitive Event Related Potentials in a double-blind, placebo-controlled study with the hemoderivative Actovegin in Age-Associated Memory Impairment. Neuropsychobiology 24: 49–56

    Google Scholar 

  • Shader RI, Harmatz JS, Salzman C (1974) A new scale for clinical assessment in geriatric populations: Sandoz Clinical Assessment Geriatric (SCAG). J Am Geriatr Soc 22: 107–113

    Google Scholar 

  • Simons RF, Russo KR, Hoffmann JE (1988) Event-related potentials and eye-movement relationships during psychophysical judgments: the biasing effect of rejected trials. J Psychophysiol 2: 27–37

    Google Scholar 

  • Smith ME, Halgren E, Sokolik M, Baudena P, Musolino A, Liegeois-Chauvel C, Chauvel P (1990) The intracranial topography of the P3 event-related potential elicited during auditory oddball. Electroencephalogr Clin Neurophysiol 76: 235–248

    Google Scholar 

  • Sokoloff P, Giros B, Martres M-P, Bouthenet M-L, Schwartz J-C (1990) Molecular cloning and characterization of a novel dopamin receptor (D3) as a target for neuroleptics. Nature 347: 146–151

    Google Scholar 

  • Squires NK, Squires KC, Hillyard SA (1975) Two varieties of long-latency positive waves evoked by unpredictable auditory stimuli in man. Electroencephalogr Clin Neurophysiol 38: 387–401

    Google Scholar 

  • Stern JA, Walrath LC, Goldstein R (1984) The endogenous eyeblink. Psychophysiology 21: 22–33

    Google Scholar 

  • Tallroth G, Lindgren M, Stenberg G, Rosen I, Agardh CD (1990) Neurophysiological changes during insulin-induced hypoglycaemia and in the recovery period following glucose infusion in type 1 (insulin-dependent) diabetes mellitus and in normal man. Diabetologia 33: 319–323

    Google Scholar 

  • Teo RKC, Ferguson DA (1986) The acute effects of ethanol on auditory event-related potentials. Psychopharmacology 90: 179–184

    Google Scholar 

  • Terzano MJ, Montonari E, Calzetti S (1983) The effect of amantadine on arousal an EEG patterns in Creutzfeldt-Jakob disease. Arch Neurol 40: 555–559

    Google Scholar 

  • Vardi J, Streifler M (1975) On synchronizing effect of amantadine-1-hydrochloride (Symmetrel) on pathological EEG activity. J Neural Transm 37: 73–73

    Google Scholar 

  • Walsleben JA, Squires NK, Rothenberger VL (1989) Auditory event-related potentials and brain dysfunction in sleep apnea. Electroencephalogr Clin Neurophysiol 74: 297–311

    Google Scholar 

  • Wasch HH, Estrin WJ, Yip P, Bowler R, Cone JE (1989) Prolongation of the P300 latency associated with hydrogen sulfide exposure. Arch Neurol 46: 902–904

    Google Scholar 

  • Weissenborn K, Scholz M, Hinrichs H, Wiltfang J, Schmidt FW, Künkel H (1990) Neurophysiological assessment of early hepatic encephalopathy. Electroencephalogr Clin Neurophysiol 75: 289–295

    Google Scholar 

  • Wesensten NJ, Badia P, Harsh J (1990) Time of day, repeated testing, and interblock interval effect on P300 amplitude. Physiol Behav 47: 653–658

    Google Scholar 

  • Whalley LJ (1989) Drug treatments of dementia. Br J Psychiatry 155: 595–611

    Google Scholar 

  • Wilcox JA, Tsuang J (1990) Psychological effects of amantadine on psychotic subjects. Pharmacopsychiatry 23: 144–146

    Google Scholar 

Download references

Author information

Author notes

  1. H. V. Semlitsch

    Present address: Sections of Clinical Psychophysiology and Pharmacopsychiatry, Department of Psychiatry, University of Vienna, Währinger Gürtel 18-20, A-1090, Wien, Austria

Authors and Affiliations

  1. Sections of Clinical Psychophysiology and Pharmacopsychiatry, Department of Psychiatry, University of Vienna, Währinger Gürtel 18-20, A-1090, Wien, Austria

    P. Anderer & B. Saletu

Authors
  1. H. V. Semlitsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Anderer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Saletu
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Semlitsch, H.V., Anderer, P. & Saletu, B. Topographic mapping of long latency “cognitive” event-related potentials (P 300): a double-blind, placebo-controlled study with amantadine in mild dementia. J Neural Transm Gen Sect 4, 319–336 (1992). https://doi.org/10.1007/BF02260080

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02260080

Keywords

Search

Navigation